

3. Sawas T, Killcoyne S, Iyer PG, et al. Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. *Gastroenterology* 2018; 155: 1720–1728.
4. Kroupa R. Barrettův jícen, rizikové faktory, léčba. *Interní Med* 2012; 14: 104–106.
5. Freeman M, Offman J, Walter MF, et al. Acceptability of the Cytosponge procedure for detecting Barrett's oesophagus: a qualitative study. *BMJ Open* 2017; 7: e013901.
6. Shaheen N, Falk GW, Iyer PG, et al. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *Am J Gastroenterol* 2016; 111: 30–50.
7. Fitzgerald RC, di Pietro M, Ragnath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. *Gut* 2014; 63: 7–42.
8. Iqbal U, Siddique O, Ovalle A, et al. Safety and efficacy of a minimally invasive cell sampling device ('Cytosponge') in the diagnosis of esophageal pathology: a systematic review. *Eur J Gastroenterol Hepatol* 2018; 30: 1261–1269.
9. Katzka AD. Recent Advances in Non-invasive Esophageal Tissue Sampling. *Curr Gastroenterol Rep* 2017; 19: 9.
10. Szoka N, Fazi J. 2019. Cytosponge™ – A SAGES Technology and Value Assessment. SAGES - Society of American Gastrointestinal and Endoscopic Surgeons (online). Dostupné z: <https://www.sages.org/publications/tavac/cytosponge/>
11. Zhou Z, Kalatskaya I, Russell D, et al. Combined EsophCap cytology and MUC2 immunohistochemistry for screening of intestinal metaplasia, dysplasia and carcinoma. *Clin Exp Gastroenterol* 2019; 12: 219–229.
12. Li X, Kleeman S, Coburn SB, et al. Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's Esophagus. *Gastroenterology* 2018; 155: 771–783.
13. Wang Z, Kambhampati S, Cheng Y, et al. Methylation Biomarker Panel Performance in EsophCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study. *Clin Cancer Res* 2019; 1: 2127–2135.
14. EsoCheck | Lucid Diagnostics | United State. Lucid Diagnostics | Biomarkers for Esophageal Cancer | New York (online). Copyright © 2019 Lucid Diagnostics (cit. 23.10.2019). Dostupné z: <https://www.lucidix.com/esocheck>
15. Moinova HR, LaFramboise T, Lutterbaugh JD, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. *Sci Transl Med* 2018; 17: pii: eaao5848.
16. Qureshi AP, Stachler MD, Haque O, et al. Biomarkers for Barrett's esophagus – a contemporary review. *Expert Rev Mol Diagn* 2018; 18: 939–946.
17. Naini VB, Souza FR, Odze DR. Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists. *Am J Surg Pathol* 2016; 40: e45–e66.
18. Mutační analýza genu p53 – Oddělení lékařské genetiky FN Brno. Oddělení lékařské genetiky FN Brno (online). Copyright © 2016 (cit. 25.10.2019). Dostupné z: <https://genetikabrno.eu/vysetrujeme/mutacni-analyza-genu-p53/>
19. Chettouh H, Mowforth O, Galeano-Dalmau N, et al. Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and nonendoscopic cytology specimens. *Gut* 2018; 67: 1942–1949.
20. Iyer PG, Taylor WR, Johnson ML, et al. Highly Discriminant Methylated DNA Markers for the Non-endoscopic Detection of Barrett's Esophagus. *Am J Gastroenterol* 2018; 113: 1156–1166.
21. Kailasam A, Mittal KS, Agrawal KD. Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma. *Clin Transl Sci* 2015; 8: 394–402.
22. Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. *Cell Death Discov* 2017; 3: 17071.
23. Jia Y, Yang Y, Brock VM, et al. Methylation of TFPI-2 is an early event of esophageal carcinogenesis. *Epigenomics* 2012; 4: 135–146.
24. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. *Blood* 2006; 108: 3646–3653.
25. Slaby O, Srovnal J, Radova L, et al. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma. *Carcinogenesis* 2015; 36: 521–527.
26. Konda AJV, Souza FR. Biomarkers of Barrett's Esophagus: From the Laboratory to Clinical Practice. *Dig Dis Sci* 2018; 63: 2070–2080.
27. Fabisiak A, Bartoszek A, Kardas G, et al. Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus. *Peptides* 2019; 115: 27–31.
28. Miller MD, Thomas DS, Islam A, et al. c-Myc and Cancer Metabolism. *Clin Cancer Res* 2012; 18: 5546–5553.
29. Ruge M, Fassan M, Zaninotto G, et al. Aurora kinase A in Barrett's carcinogenesis. *Hum Pathol* 2010; 41: 1380–1386.
30. CGB laboratoře. CGB laboratoře (online). Copyright © 2016, CGB laboratoř a.s. (cit. 20.09.2019). Dostupné z: <http://www.pathology.cz/>
31. Groisman MG, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. *Mod Pathol* 2004; 17: 1282–1288.
32. Lalkhen GA, McCluskey A. Clinical tests: sensitivity and specificity. *Continuing Education in Anaesthesia Critical Care & Pain* 2008; 8: 221–223.
33. Thota, Chak. Mass Screening for Barrett's esophagus: Myth or Reality? *Clin Gastroenterol Hepatol* 2018; 17: 610–612.
34. Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. *BMJ* 2010; 10; 341: c4372.
35. Ross-Innes CS, DeBiram-Beecham I, O'Donovan M, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. *PLoS Med* 2015; 29; e1001780.
36. Ross-Innes CS, Chettouh H, Achilleos A, et al. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. *Lancet Gastroenterol Hepatol*. 2017; 2: 23–31.
37. Kroupa R, Konečný Š, Dolina J. Současné trendy v diagnostice a léčbě refluxní nemoci jícnu. *Vnitř Lék* 2018; 64: 588–594.
38. Svoboda P, Dítě P, Klvaňa P, et al. Rizikové faktory a prediktory progresu Barrettova jícnu do adenokarcinomu. *Vnitř Lék* 2014; 60: 467–473.